Literature DB >> 23067060

Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada.

J Kraft1, V Blanchette, P Babyn, B Feldman, S Cloutier, S Israels, M Pai, G-E Rivard, S Gomer, M McLimont, R Moineddin, A S Doria.   

Abstract

BACKGROUND/
OBJECTIVES: Tailored primary prophylaxis (TPP) is a reduced-intensity treatment program for hemophiliacs with the goal of preventing arthropathy. Our primary aim was to evaluate the joint outcomes of treated subjects using magnetic resonance imaging (MRI) and physical examination as outcome measures.
METHODS: Ankles, elbows and knees (index joints) of 24 subjects (median [range] age at start of therapy, 1.6 [1-2.5] years) with severe hemophilia A enrolled in the Canadian Hemophilia Primary Prophylaxis Study (CHPS) were examined by MRI at a median age of 8.8 years (range 6.2-11.5 years). Subjects were treated with TPP using a recombinant factor VIII concentrate, starting once weekly and escalating in frequency and dose according to frequency of bleeding.
RESULTS: Osteochondral changes (cartilage loss/subchondral bone damage) were detected in 9% (13/140) of the index joints and 50% (12/24) of study subjects. Osteochondral changes were restricted to joints with a history of clinically reported joint bleeding. Soft tissue changes were detected in 31% (20/65) of index joints with no history of clinically reported bleeding (ankles 75% (12/16); elbows 19% (6/32); and knees 12% (2/17)). In these apparently 'bleed free' index joints hemosiderin deposition was detected by MRI in 26% (17/65) of joints (ankles 63% (10/16); elbows 16% (5/32), and knees 12% (2/17)).
CONCLUSION: TPP did not completely avoid the development of MRI-detected structural joint changes in hemophilic boys in this prospective study. A longer period of follow-up is required for assessment of the longitudinal course of these early changes in hemophilic arthropathy, detected using a sensitive imaging technique (MRI).
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Year:  2012        PMID: 23067060     DOI: 10.1111/jth.12025

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  13 in total

1.  [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].

Authors:  Jin-Mu Zhuang; Xue-Yan Sun; Xuan Zhou; Zhu-Qin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

2.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

3.  Inflammatory focal bone destruction in femoral heads with end-stage haemophilic arthropathy: a study on clinic samples with micro-CT and histological analyses.

Authors:  S Zhang; C Lu; J Ying; P Wang; T Xu; D Chen; H Jin; P Tong
Journal:  Haemophilia       Date:  2015-09-20       Impact factor: 4.287

Review 4.  Orthopedic disorders of the knee in hemophilia: A current concept review.

Authors:  E Carlos Rodriguez-Merchan; Leonard A Valentino
Journal:  World J Orthop       Date:  2016-06-18

5.  Loss of extracellular matrix from articular cartilage is mediated by the synovium and ligament after anterior cruciate ligament injury.

Authors:  C M Haslauer; K A Elsaid; B C Fleming; B L Proffen; V M Johnson; M M Murray
Journal:  Osteoarthritis Cartilage       Date:  2013-09-13       Impact factor: 6.576

6.  [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].

Authors:  Xueyan Sun; Jinmu Zhuang; Xuan Zhou; Huiping Li; Zhuqin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30

Review 7.  Aspects of prophylactic treatment of hemophilia.

Authors:  Rolf Ljung
Journal:  Thromb J       Date:  2016-10-04

Review 8.  Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.

Authors:  Angiola Rocino; Massimo Franchini; Antonio Coppola
Journal:  J Clin Med       Date:  2017-04-17       Impact factor: 4.241

9.  Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.

Authors:  J Oldenburg; R Zimmermann; O Katsarou; G Theodossiades; E Zanon; B Niemann; E Kellermann; B Lundin
Journal:  Haemophilia       Date:  2014-12-02       Impact factor: 4.263

10.  Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting.

Authors:  Nihal Bakeer; Saunya Dover; Paul Babyn; Brian M Feldman; Annette von Drygalski; Andrea S Doria; Danial M Ignas; Audrey Abad; Cindy Bailey; Ian Beggs; Eric Y Chang; Amy Dunn; Sharon Funk; Sridhar Gibikote; Nicholas Goddard; Pamela Hilliard; Shyamkumar N Keshava; Rebecca Kruse-Jarres; Yingjia Li; Sébastien Lobet; Marilyn Manco-Johnson; Carlo Martinoli; James S O'Donnell; Olympia Papakonstantinou; Helen Pergantou; Pradeep Poonnoose; Felipe Querol; Alok Srivastava; Bruno Steiner; Karen Strike; Merel Timmer; Pascal N Tyrrell; Logi Vidarsson; Victor S Blanchette
Journal:  Res Pract Thromb Haemost       Date:  2021-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.